Triple Vaccine for Pigs Released: A Major Breakthrough in Swine Health Management

:

Breakthrough in Swine Health: New Vaccine Offers Triple Protection in Argentina

Buenos Aires – A pioneering vaccine, Circumvent® CML, is now available in Argentina, representing a meaningful leap forward in protecting pigs against major diseases.Developed by MSD Animal Health, this unique vaccine provides simultaneous protection against three prevalent conditions with a single application, transforming preventative care for swine populations.

The novel vaccine addresses critical threats to porcine health, including PCV2 (porcine circovirus type 2), which leads to weight loss, stunted growth, and increased mortality. Circumvent® CML also provides immunity against Mycoplasma hyopneumoniae, a cause of severe pneumonia, and Lawsonia intracellularis, the agent responsible for ileitis-a debilitating intestinal infection that hinders nutrient absorption.

“With Circumvent® CML we are transforming the way in which swine health in Argentina is protected. It is indeed a vaccine that not only offers triple protection in a single dose but also provides convenience, value and specific results, raising animal welfare and the productivity of farms,” stated Guillermo Racca, technical manager of MSD Argentine Animal health.

Innovation for Efficiency and Animal Welfare

Circumvent® CML has been meticulously designed to minimize stress for animals and enhance operational efficiency for producers. Its single-dose administration protocol dramatically reduces the number of necessary injections, decreasing animal handling and associated stress, while streamlining the vaccination process. The concentrated formula also reduces storage demands and waste generation, furthering sustainable swine production practices.

The vaccine’s efficacy is backed by a robust body of scientific evidence, including ten international registration studies demonstrating consistent and sustained immune responses. It leverages proven antigens and adjuvants from existing, well-established vaccines.

A New Standard in Swine Disease Prevention

The introduction of Circumvent® CML marks a new era in preventing swine diseases in Argentina.This innovative approach combines science, practicality, and a proactive focus on promoting animal wellbeing and farm productivity.

Disease	Cause	Symptoms/Impact
PCV2 (Porcine Circovirus Type 2)	Virus	Weight loss, poor growth, increased mortality, reproductive issues
Mycoplasma hyopneumoniae	Bacteria	Pneumonia, lung lesions, reduced performance
Lawsonia intracellularis	Bacteria	Ileitis (proliferative enteritis), impaired nutrient absorption, reduced growth

Did you know? The economic impact of these three diseases globally is significant, costing the swine industry billions annually in lost productivity and treatment costs.

Pro Tip: Discuss vaccination protocols with your veterinarian to determine the best schedule for your farm’s specific needs and risk factors.

Is Circumvent® CML a cost-effective solution for swine farmers?

The vaccine’s single-dose format and reduced handling requirements translate into significant time and labor savings, ultimately increasing efficiency on the farm.

How does the scientific evidence support the effectiveness of Circumvent® CML?

The vaccine is supported by ten international registration studies and uses antigens and adjuvants already proven in other accomplished vaccines, ensuring a robust and sustained immune response.

What are the key economic benefits observed in swine operations following implementation of the triple vaccine, as demonstrated in the Iowa case study?

Understanding the New triple Vaccine

A groundbreaking advancement in swine health has arrived with the release of a novel triple vaccine designed to combat three meaningful diseases affecting pig populations globally: Porcine Reproductive and Respiratory Syndrome (PRRS), Mycoplasma hyopneumoniae (MHy), and Actinobacillus pleuropneumoniae (APP). This innovative vaccine represents a significant step forward in preventative veterinary medicine, offering enhanced protection and improved herd health. the growth focuses on a modified-live virus (MLV) approach, stimulating a robust immune response in pigs.

Diseases Targeted by the Vaccine

This triple vaccine addresses three highly prevalent and economically damaging diseases in the swine industry:

* Porcine Reproductive and Respiratory Syndrome (PRRS): A viral disease causing reproductive failure in sows and respiratory illness in pigs of all ages. PRRS leads to significant economic losses due to reduced piglet viability, slower growth rates, and increased treatment costs.

* Mycoplasma hyopneumoniae (MHy): A bacterial infection primarily affecting the respiratory system, causing pneumonia and reduced growth performance. Chronic MHy infections can lead to pleuropneumonia and lung lesions.

* Actinobacillus pleuropneumoniae (APP): Another bacterial infection causing fibrinous pleuropneumonia and septicemia. APP is characterized by sudden death,fever,and respiratory distress. Effective APP vaccination is crucial for minimizing outbreaks.

Vaccine Composition and Mechanism of Action

The newly released vaccine utilizes a carefully formulated combination of attenuated (weakened) viruses and bacterial strains. each component is designed to elicit a specific immune response:

1. PRRS Component: A modified-live PRRS virus strain, inducing both humoral (antibody-mediated) and cellular immunity.
2. mhy Component: A live, attenuated strain of Mycoplasma hyopneumoniae, promoting the development of long-lasting immunity.
3. APP Component: A genetically modified strain of Actinobacillus pleuropneumoniae, expressing key surface antigens to stimulate a protective immune response.

The combined approach allows for a synergistic effect, enhancing the overall immune response and providing broader protection against thes three diseases. the vaccine works by mimicking a natural infection, prompting the pig’s immune system to produce antibodies and activate immune cells without causing clinical signs of illness.

Administration and Dosage Guidelines

Proper vaccine administration is critical for maximizing efficacy. The triple vaccine is typically administered via intramuscular injection, following the manufacturer’s recommended dosage schedule.

* Primary Vaccination: Pigs should receive the primary vaccination series between 6-8 weeks of age.

* Booster Vaccination: A booster dose is recommended 2-4 weeks later to enhance and prolong immunity.

* Sows: Sows should be vaccinated before breeding to provide passive immunity to their piglets through colostrum.

Veterinarians should consult the product label for specific dosage instructions and administration guidelines. Proper handling and storage of the vaccine are also essential to maintain its potency.Swine vaccination protocols should be tailored to the specific needs of each farm.

Benefits of a Triple Vaccine Approach

Implementing a triple vaccine strategy offers several key advantages over individual vaccinations:

* Reduced Labor Costs: Administering a single vaccine reduces the time and labor required for vaccination programs.

* Improved Compliance: Simplifying the vaccination schedule increases the likelihood of complete vaccination coverage within the herd.

* Enhanced Herd Immunity: Simultaneous protection against three major diseases leads to stronger overall herd immunity.

* Economic Benefits: Reduced disease incidence translates to lower treatment costs, improved growth rates, and increased profitability for swine producers.

* Reduced Antibiotic Use: Proactive vaccination reduces the need for antibiotic treatment, contributing to responsible antibiotic stewardship.

Real-World Impact: Case Study from Iowa

A large-scale swine operation in Iowa implemented the triple vaccine in a trial program during the fall of 2024.Prior to vaccination, the farm experienced frequent outbreaks of PRRS, MHy, and APP, resulting in significant economic losses. Following the implementation of the triple vaccine, the farm reported a:

* 60% reduction in PRRS-related mortality.

* 45% decrease in antibiotic usage for respiratory disease.

* Improved average daily gain (ADG) of 5% in finishing pigs.

These results demonstrate the potential of the triple vaccine to substantially improve swine health and profitability.

Monitoring and Surveillance Post-Vaccination

While the triple vaccine provides robust protection, ongoing monitoring and surveillance are crucial for maintaining